Abstract: A human CD40L-specific Tn3 molecule and therapeutic uses thereof for the treatment of lupus nephritis are provided herein. Also provided are therapeutic regimens that comprise a CD40L-specific Tn3 scaffold.

Abstract: Methods of treating neuromyelitis optica spectrum disorder (NMOSD) are disclosed herein. In particular, methods of treating NMOSD in a subject identified as having a higher or lower level of NMOSD-disease activity, e.g., by serum glial fibrillary acidic protein concentration, are provided.

Abstract: Methods for using an anti-CD19 antibody to treat autoimmune disease are disclosed herein. In particular the use of VIB551, a humanised, affinity-optimised, afucosylated IgG1 kappa monoclonal antibody to treat Neuromyelitis optica spectrum disorder.

Abstract: A sensor apparatus may include a conduit structure including an inner surface defining a conduit extending through an interior of the conduit structure, an inlet structure coupled to an end of the conduit structure, and a plurality of sensor devices in hydrodynamic contact with the conduit. The inlet structure may couple with an outlet end of an external tobacco element to hold the outlet end of the external tobacco element in fluid communication with an inlet opening of the conduit structure, such that the conduit structure may receive a generated aerosol from the external tobacco element at the inlet opening, and draw an instance of aerosol through the conduit towards an outlet opening. The instance of aerosol may include at least a portion of the generated aerosol. Each sensor device may generate sensor data indicating a pressure of the instance of aerosol through a separate portion of the conduit.

Abstract: A sensor apparatus may include a conduit structure including an inner surface defining a conduit extending through an interior of the conduit structure, an inlet structure coupled to an end of the conduit structure, and a plurality of sensor devices in hydrodynamic contact with the conduit. The inlet structure may couple with an outlet end of an external tobacco element to hold the outlet end of the external tobacco element in fluid communication with an inlet opening of the conduit structure, such that the conduit structure may receive a generated aerosol from the external tobacco element at the inlet opening, and draw an instance of aerosol through the conduit towards an outlet opening. The instance of aerosol may include at least a portion of the generated aerosol. Each sensor device may generate sensor data indicating a pressure of the instance of aerosol through a separate portion of the conduit.

Abstract: The present disclosure relates to methods for treating or preventing immune-mediated pulmonary injury (IMPI) in a subject in need thereof, the method comprising administering to the subject an anti-Type I interferon (anti-T1i) therapy that blocks the activity, function or production of Type I interferon (T1i) in the subject, wherein the anti-T1i therapy is administered to the subject infected with a respiratory virus that causes a delayed T1i response in the subject.

Abstract: The present disclosure is related to methods of treating autoimmune disorders in a subject comprising administering immunoglobulin-like transcript 7 (ILT7) binding proteins to a subject having elevated type I interferon gene signature (IFNGS). The present disclosure also relates to methods of reducing pDCs in tissues comprising administering an ILT7-binding protein to a subject in need thereof.

Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an anti-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.

Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).

Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).

Abstract: A human CD40L-specific Tn3 molecule and therapeutic uses thereof.

Abstract: A sensor apparatus may include a conduit structure including an inner surface defining a conduit extending through an interior of the conduit structure, an inlet structure coupled to an end of the conduit structure, and a plurality of sensor devices in hydrodynamic contact with the conduit. The inlet structure may couple with an outlet end of an external tobacco element to hold the outlet end of the external tobacco element in fluid communication with an inlet opening of the conduit structure, such that the conduit structure may receive a generated aerosol from the external tobacco element at the inlet opening, and draw an instance of aerosol through the conduit towards an outlet opening. The instance of aerosol may include at least a portion of the generated aerosol. Each sensor device may generate sensor data indicating a pressure of the instance of aerosol through a separate portion of the conduit.

Abstract: A sensor apparatus may include a conduit structure including an inner surface defining a conduit extending through an interior of the conduit structure, an inlet structure coupled to an end of the conduit structure, and a plurality of sensor devices in hydrodynamic contact with the conduit. The inlet structure may couple with an outlet end of an external tobacco element to hold the outlet end of the external tobacco element in fluid communication with an inlet opening of the conduit structure, such that the conduit structure may receive a generated aerosol from the external tobacco element at the inlet opening, and draw an instance of aerosol through the conduit towards an outlet opening. The instance of aerosol may include at least a portion of the generated aerosol. Each sensor device may generate sensor data indicating a pressure of the instance of aerosol through a separate portion of the conduit.

Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.

Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).

Abstract: A sensor apparatus may include a conduit structure including an inner surface defining a conduit extending through an interior of the conduit structure, an inlet structure coupled to an end of the conduit structure, and a plurality of sensor devices in hydrodynamic contact with the conduit. The inlet structure may couple with an outlet end of an external tobacco element to hold the outlet end of the external tobacco element in fluid communication with an inlet opening of the conduit structure, such that the conduit structure may receive a generated aerosol from the external tobacco element at the inlet opening, and draw an instance of aerosol through the conduit towards an outlet opening. The instance of aerosol may include at least a portion of the generated aerosol. Each sensor device may generate sensor data indicating a pressure of the instance of aerosol through a separate portion of the conduit.

Abstract: A mobile computing device is disclosed. In some aspects, the mobile computing device may execute a first application using one or more processors, and may receive, during execution of the first application, a user selection of a shift key. The mobile computing device may transition a state of the shift key from an unlocked non-shift state to a shift state based on the user selection. The mobile computing device may change the execution of the first application to an execution of a second application, and clear the state of the shift key in response to changing the execution from the first application to the second application.

Abstract: A mobile computing device is disclosed. In some aspects, the mobile computing device may execute a first application using one or more processors, and may receive, during execution of the first application, a user selection of a shift key. The mobile computing device may transition a state of the shift key from an unlocked non-shift state to a shift state based on the user selection. The mobile computing device may change the execution of the first application to an execution of a second application, and clear the state of the shift key in response to changing the execution from the first application to the second application.

Abstract: A mobile computing device is disclosed. In some aspects, the mobile computing device may execute a first application using one or more processors, and may receive, during execution of the first application, a user selection of a shift key. The mobile computing device may transition a state of the shift key from an unlocked non-shift state to a shift state based on the user selection. The mobile computing device may change the execution of the first application to an execution of a second application, and clear the state of the shift key in response to changing the execution from the first application to the second application.

Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.